Ixazomib: An Oral Proteasome Inhibitor for the Treatment of Multiple Myeloma
Krista G. Ramirez, PharmD, BCPS
Greenville Health System, Greer, South Carolina
Krista G. Ramirez, PharmD, BCPS, 845-D South Buncombe Road, Greer, South Carolina 29650. E-mail: KRamirez@ghs.org
J Adv Pract Oncol 2017;8:401–405 |
© 2017 Harborside Press®
The FDA approval of ixazomib for use in combination with lenalidomide and dexamethasone for patients with multiple myeloma who have received at least one prior therapy signalled the arrival of the first oral proteasome inhibitor, allowing advanced practitioners to provide multiple myeloma patients an exclusively oral triplet therapy.
For access to the full length article, please sign in